MiMedx Group, Inc. is a biopharmaceutical company that develops and markets regenerative biologics utilizing human placental tissue allografts. The company's product portfolio includes EpiFix, AmnioFix, EpiCord, and EpiBurn. These products are used in the treatment of chronic wounds, burns, and surgical soft tissue damage. MiMedx Group, Inc. is headquartered in Marietta, Georgia and operates in the United States, Europe, and Asia.